Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5767517 | 0.90 | LMNA (0.37) | GPR119MEN1KMT2AKDM4E | |
| SCHEMBL5763519 | 0.87 | GPR119 (0.44) | GPR119KDM4E | |
| SCHEMBL5767222 | 0.81 | LMNA (0.36) | GPR119MEN1KMT2A | |
| SCHEMBL4720180 | 0.79 | GPR119 (0.46) | GPR119KDM4E | |
| SCHEMBL3943472 | 0.77 | GAA (0.46) | GPR119KDM4E | |
| SCHEMBL3939247 | 0.74 | CYP3A4 (0.53) | GPR119KDM4E | |
| SCHEMBL3942539 | 0.73 | CYP3A4 (0.46) | GPR119KDM4E | |
| SCHEMBL3936734 | 0.73 | CYP3A4 (0.51) | GPR119KDM4E | |
| SCHEMBL13941032 | 0.71 | CYP3A4 (0.56) | GPR119KDM4E | |
| SCHEMBL3945258 | 0.70 | CYP3A4 (0.43) | GPR119MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644340-A1 | N-{'4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL]ALKYL}-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005000822-A1 | N-{‘4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL!ALKYL}-N-HYDROXYFOMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-01-06 | — | — | WO | disclosed |